Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07032272 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07032272 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT07032272, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to support the development of remibrutinib dosing recommendations for patients with impaired renal function.
Interventions
- DRUG remibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2025-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07032272
The ClinicalTrials.gov registry entry for NCT07032272 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which remibrutinib is the first listed.
NCT07032272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07032272 about?
NCT07032272 is a clinical study titled "A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.". The purpose of this study is to support the development of remibrutinib dosing recommendations for patients with impaired renal function.
What is the current status of trial NCT07032272?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-07-23. Estimated completion is 2025-10-14.
What interventions are being tested in trial NCT07032272?
The interventions under investigation include: remibrutinib (DRUG).
Who is sponsoring clinical trial NCT07032272?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.